Our Speakers

Ron Weathermon

Teva Pharmaceuticals

Global Head of Innovation and Scientific Excellence

The best Medical Affairs strategy is to have an end-to-end communications strategy

We think we are communicating the value of Medical Affairs, but we do little to understand why our stakeholders are not listening? In this session:

• You will learn to understand where your target audience is: from Awareness and Appetite to Ability and Action
• You will learn simple solutions to evaluate the level of engagement and connection of R&D, Medical, and Commercial associates and where/how to meet them where they are
• Finally, you will receive tips on how to build an effective Medical Affairs communication infrastructure from the ground up to 'SELL' the value of Medical Affairs

Kaja Zarakowska

UCB

Head of Medical Diagnosis Innovation & Care Pathways

Partnering for Progress and Elevating Medical Affairs: Strategies for Impactful Leadership and Collaboration

• Cross-Functional Collaboration as a Catalyst to achieve Medical Affairs Excellence
• Expanding company's diagnosis capabilities to maximize asset value by actively integrating expert knowledge, patient voice, and cutting-edge technologies as an ecosystem leading partner
• Diagnosis as a key moment in the care pathway. Enhancing support for Asset/TA Teams by structuring diagnosis is crucial to ensure earlier, more accurate, and equitable diagnosis for patients

Olga Andreeva

Novo Nordisk A/S

Global Medical Excellence Director

Bridging the Gap: Post-Trial Access Strategies for Patients Exiting Clinical Trials

• Case examples from Novo Nordisk on how Expanded Access pathways can be leveraged to ensure continuity of treatment post-trial.
• Why early strategic planning and governance are essential - and what happens when they are missing.
• Navigating legal and ethical obligations when trials end without a clear access pathway.
• How to pivot in real time: building post-trial access solutions under time and resource constraints. Considerations for scalability: moving from individual solutions to sustainable frameworks across trials and geographies.

Vivek Mukhatyar

Pfizer

GenAI Medical Engagement Lead

Harnessing the GenAI opportunity in Medical Affairs

• Unlocking the power of AI in Medical Affairs
• The Integration of AI powered Solutions in Medical Affairs - Strategic leap toward optimized performance and enhanced patient care
• AI-driven medical engagement

Thomas Lanz

Boehringer Ingelheim

Medical Affairs Performance Lead

Aiming for impact - transforming Medical Affairs towards leading value creation

• Mindset shift of Medical Affairs role to create tangible external impact which is to accelerate clinical adoption of innovation
• Transforming the Medical Affairs function and laying out a vision for the future of Medical Affairs
• State of the art Medical Metrics / KPI Framework that allows for tangible demonstration of Medical Affairs value
• Case study of a hands-on model for evidence-based engagement to optimize care pathways and demonstrate tangible impact

Loucif Léo OUYAHIA

Jazz Pharma

Head Of Digital Healthcare

AI impact in Medical Affairs : Congress Management

• Use cases discussions
• Challenges for AI
• The future of Digital Health in Medical Affairs